X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2761) 2761
diabetes mellitus, type 2 - drug therapy (1957) 1957
dipeptidyl-peptidase iv inhibitors - therapeutic use (1887) 1887
hypoglycemic agents - therapeutic use (1372) 1372
male (1354) 1354
type 2 diabetes (1097) 1097
female (1092) 1092
animals (1024) 1024
endocrinology & metabolism (991) 991
diabetes (914) 914
middle aged (870) 870
glucagon-like peptide-1 (745) 745
aged (717) 717
pharmacology & pharmacy (641) 641
dipeptidyl-peptidase iv inhibitors - adverse effects (614) 614
dipeptidyl-peptidase iv inhibitors - pharmacology (609) 609
sitagliptin (593) 593
treatment outcome (587) 587
diabetes mellitus, type 2 - blood (562) 562
glucose (547) 547
dipeptidyl peptidase 4 - metabolism (544) 544
adamantane - analogs & derivatives (505) 505
hypoglycemic agents - adverse effects (490) 490
metformin (482) 482
double-blind (474) 474
adult (455) 455
diabetes mellitus (453) 453
glycemic control (443) 443
drug therapy, combination (441) 441
hypoglycemic agents (437) 437
insulin (430) 430
dipeptidyl peptidase-4 inhibitor (427) 427
blood glucose - metabolism (419) 419
blood glucose - drug effects (395) 395
metformin - therapeutic use (395) 395
sitagliptin phosphate (384) 384
care and treatment (377) 377
adamantane - therapeutic use (373) 373
analysis (369) 369
risk factors (368) 368
mice (367) 367
dipeptidyl-peptidase iv inhibitors - administration & dosage (363) 363
vildagliptin (359) 359
hypoglycemic agents - pharmacology (353) 353
peptidase (334) 334
research (331) 331
diabetes mellitus, type 2 - complications (324) 324
hypoglycemic agents - administration & dosage (318) 318
rats (314) 314
safety (312) 312
triazoles - therapeutic use (310) 310
drug therapy (308) 308
pyrazines - therapeutic use (304) 304
type 2 diabetes mellitus (300) 300
glycated hemoglobin a - metabolism (299) 299
internal medicine (293) 293
diabetes therapy (291) 291
dipeptidyl peptidase-4 inhibitors (286) 286
efficacy (285) 285
medicine, general & internal (285) 285
beta-cell function (272) 272
dpp-4 inhibitor (270) 270
type-2 diabetes-mellitus (270) 270
diabetes mellitus, type 2 - metabolism (269) 269
glucagon (267) 267
peptides (267) 267
pyrrolidines - therapeutic use (262) 262
dextrose (258) 258
sulfonylurea compounds - therapeutic use (253) 253
nitriles - therapeutic use (241) 241
dipeptidyl-peptidase-iv (240) 240
glp-1 (239) 239
clinical trials (234) 234
incretins - therapeutic use (234) 234
therapy (234) 234
double-blind method (232) 232
improves glycemic control (232) 232
insulin resistance (228) 228
health aspects (227) 227
dipeptidyl-peptidase iv inhibitors (224) 224
linagliptin (221) 221
mellitus (221) 221
hyperglycemia (217) 217
medicine & public health (213) 213
risk (213) 213
hypoglycemia (212) 212
abridged index medicus (210) 210
medicine, research & experimental (204) 204
cardiac & cardiovascular systems (201) 201
dpp-4 inhibitors (196) 196
diabetes mellitus, type 2 - physiopathology (194) 194
dosage and administration (194) 194
time factors (194) 194
insulin - therapeutic use (193) 193
biochemistry & molecular biology (192) 192
dipeptidyl peptidase-iv (191) 191
hypoglycemia - chemically induced (187) 187
randomized controlled trials as topic (184) 184
glycated hemoglobin a - analysis (183) 183
inhibitors (180) 180
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3281) 3281
Japanese (38) 38
French (29) 29
German (29) 29
Spanish (21) 21
Hungarian (8) 8
Czech (7) 7
Italian (5) 5
Dutch (4) 4
Russian (4) 4
Chinese (3) 3
Danish (2) 2
Polish (2) 2
Croatian (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Best Practice & Research: Clinical Endocrinology & Metabolism, ISSN 1521-690X, 2007, Volume 21, Issue 4, pp. 517 - 533
.... Several DPP-4 inhibitors are in clinical development. Most experience so far has been with sitagliptin (Merck... 
Endocrinology & Metabolism | treatment | dipeptidyl peptidase 4 | sitagliptin | type-2 diabetes | vildagliptin | glucagon-like peptide-1 | GLYCEMIC CONTROL | DIPEPTIDYL-PEPTIDASE-IV | INSULIN-SECRETION | IMPROVED GLUCOSE-TOLERANCE | BETA-CELL FUNCTION | METFORMIN-TREATED PATIENTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PLASMA-GLUCOSE | 7-36 AMIDE | Triazoles - adverse effects | Metformin - therapeutic use | Humans | Body Weight - drug effects | Pyrrolidines - adverse effects | Substrate Specificity | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Thiazolidinediones - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Hypoglycemia - chemically induced | Protease Inhibitors - therapeutic use | Insulin Secretion | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Pioglitazone | Insulin - metabolism | Animals | Dipeptidyl-Peptidase IV Inhibitors | Lipid Metabolism - drug effects | Pyrazines - adverse effects | Glucagon - metabolism | Vildagliptin | Glucagon-Like Peptide 1 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Insulin - therapeutic use | Nitriles - therapeutic use | Clinical Medicine | Other Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Adamantane/adverse effects Adamantane/analogs & derivatives Adamantane/therapeutic use Animals Antigens | Annan klinisk medicin | Combination Glucagon/secretion Glucagon-Like Peptide 1/antagonists & inhibitors Glucagon-Like Peptide 1/physiology Humans Hypoglycemia/chemically induced Hypoglycemic Agents/therapeutic use Insulin/secretion Insulin/therapeutic use Lipid Metabolism/drug effects Metformin/therapeutic use Nitriles/adverse effects Nitriles/therapeutic use Protease Inhibitors/therapeutic use Pyrazines/adverse effects Pyrazines/therapeutic use Pyrrolidines/adverse effects Pyrrolidines/therapeutic use Substrate Specificity Thiazolidinediones/therapeutic use Triazoles/adverse effects Triazoles/therapeutic use | Type 2/drug therapy Drug Therapy | Klinisk medicin | CD26/antagonists & inhibitors Body Weight/drug effects Diabetes Mellitus
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2014, Volume 36, Issue 12, pp. 2072 - 2079
.... Methods This is a systematic review of data published in full papers and abstract form using the terms DPP-IV inhibitors and heart failure published since October 2013... 
Internal Medicine | Medical Education | DPP-IV inhibition | cardiovascular disease | heart failure | type 2 diabetes | Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) | Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD) | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | MYOCARDIAL-INFARCTION | SAXAGLIPTIN | HUMANS | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 trial | IMPACT | CLINICAL-TRIALS | IMPROVES | PHARMACOLOGY & PHARMACY | TYPE-2 DIABETES-MELLITUS | CARDIOVASCULAR RISK | Dipeptides - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptides - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Pyrrolidines - adverse effects | Uracil - therapeutic use | Hospitalization | Pyrrolidines - therapeutic use | Uracil - adverse effects | Piperidines - therapeutic use | Piperidines - adverse effects | Adamantane - therapeutic use | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Heart Failure - chemically induced | Adamantane - adverse effects | Adamantane - analogs & derivatives | Nitriles - therapeutic use | Sitagliptin Phosphate - adverse effects | Uracil - analogs & derivatives | Heart failure | Regulatory agencies | Heart attacks | Peptides | Mortality | Cardiovascular disease | FDA approval | Patients | Studies | Databases | Diabetes | Drug therapy | Acute coronary syndromes
Journal Article
Diabetes care, ISSN 1935-5548, 2011, Volume 34, Issue Supplement_2, pp. S276 - S278
Journal Article
Nature reviews. Endocrinology, ISSN 1759-5037, 2016, Volume 12, Issue 10, pp. 566 - 592
Journal Article
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 2018, Volume 20, Issue 5, pp. 1111 - 1120
..., such as a sodium‐glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase‐4 (DPP‐4) inhibitors. This may provide a more robust and sustained anti‐hyperglycaemic effect... 
clinical trial | glycaemic control | type 2 diabetes | DPP‐IV inhibitor | SGLT2 inhibitor | phase III study | DPP-IV inhibitor | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | MONOTHERAPY | EFFICACY | SAFETY | COMBINATION | BLOOD-PRESSURE | GLUCOSE COTRANSPORTER 2 | THERAPY | ENDOCRINOLOGY & METABOLISM | EMPAGLIFLOZIN | Glycated Hemoglobin A - analysis | Overweight - complications | Metformin - therapeutic use | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Drug Therapy, Combination - adverse effects | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - administration & dosage | Female | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Double-Blind Method | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Diabetes Mellitus, Type 2 - blood | Sitagliptin Phosphate - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Sitagliptin Phosphate - adverse effects | Hypertension | Type 2 diabetes | Medical research | Care and treatment | Body weight | Clinical trials | Glycosylated hemoglobin | Mycoses | Complications and side effects | Analysis | Medicine, Experimental | Urinary tract infections | Hypoglycemic agents | Diabetes therapy | Diabetes mellitus | Hemoglobin | Blood pressure | Urinary tract | Diabetes | Metformin | Hypoglycemia | Diabetes mellitus (non-insulin dependent) | Evidence-based medicine | Original
Journal Article
Atherosclerosis, ISSN 0021-9150, 2013, Volume 227, Issue 2, pp. 349 - 354
Journal Article
Journal Article